Description

DE-102 (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Summary

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

View Full Report at: http://www.marketresearchreports.biz/analysis/247116

Santen Pharmaceuticals pipeline candidate, DE-102 (betamethasone), is a steroid microsphere drug undergoing Phase II/III studies in Japan for the treatment of DME and ME-BRVO. Betamethasone is a potent steroid of the glucocorticoid class, with both anti-inflammatory and immunosuppressive properties. In preclinical studies, DE-102 demonstrated sustained efficacy when injected around the affected area, prompting Santen to develop the drug using a new delivery technology.

Scope

- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on DE-102 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for DE-102 for the top country from 2013 to 2023.
- Sales information covered for Japan

Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/247116

List of Tables

Table 1: ARM System Classification of AMD 21
Table 2: Symptoms of AMD 22
Table 3: National and International Treatment Guidelines for ME and AMD 35
Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013 36
Table 5: Leading Treatments for ME and AMD, 2014 51
Table 6: Unmet Needs and Opportunities in ME and AMD 53
Table 7: Promising Drugs in Clinical Development for ME and AMD 74
Table 8: Comparison of Drugs in Development for ME and AMD, 2014 75
Table 9: Product Profile - DE-102 78
Table 10: DE-102 SWOT Analysis, 2014 81
Table 11: Global Sales Forecast ($m) for DE-102, 2013-2023 82
Table 12: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 104

1.2 List of Figures

Figure 1: Anatomy of the Eye and Macula 14
Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD 23
Figure 3: Color Fundus Photographs of Dry and Wet AMD 23
Figure 4: FAF Imaging of GA 24
Figure 5: Imaging of wAMD 25
Figure 6: CMT in DME 31
Figure 7: RVOs (BRVO and CRVO) on an FA 31
Figure 8: Increased CRT in ME-RVO 32
Figure 9: ME Clinical Treatment Flowchart 42
Figure 10: AMD Clinical Treatment Flowchart 49
Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023 76
Figure 12: DE-102s Clinical Development in DME and ME-BRVO 78
Figure 13: Clinical and Commercial Positioning of DE-102 80

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of DE-102 performance.
- Obtain sales forecast for DE-102 from 2013-2023 in top country (Japan).


Browse all latest Articles of Market Research Reports at:http://www.marketresearchreports.biz/articles


About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Browse Our Press Releases by Prnewswire: http://www.prnewswire.com/news/marketresearchreports.biz

Contact

Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]